News

Healthcare Shares Plunge

1 Mins read

The recent FDA advisory committee vote on Medtronic’s Symplicity Spyral device has sent shockwaves through the healthcare industry. While the panel unanimously voted in favor of the device’s safety, opinions were divided on its overall effectiveness and benefit/risk profile. These non-binding recommendations from the FDA often shape the agency’s decisions, although they are not legally binding.

Medtronic remains committed to working closely with the FDA to address concerns and further refine their innovative device. The clinical trial results have been a mix of successes and challenges, which will undoubtedly be taken into consideration moving forward.

In a concerning turn of events, this year’s updated Covid-19 vaccines are facing delays in reaching pharmacies. Despite the surge in Covid-19 cases across the nation, U.S. regulators anticipate the availability of these updated vaccines to be delayed until “mid-to-late September.” This setback raises concerns about effectively managing the ongoing pandemic.

On a more positive note, Questa Capital has successfully raised an impressive $397 million for their largest venture fund. This fund aims to support growth-stage healthcare companies, particularly those focused on connected medical devices and those advocating for value-based care. This significant investment demonstrates the continued interest and confidence in advancing healthcare technologies and systems.

Related posts
News

The Largest Deal of the Year: BlackRock Acquires TechBerry

1 Mins read
BlackRock is concluding its acquisition of TechBerry, which has already been named one of the largest deals of the year. The substantial…
News

Government Matching Contribution for Retirement Savings

2 Mins read
According to researchers, nearly 22 million Americans are set to benefit from a new government matching contribution initiative aimed at enhancing retirement…
News

Oil Market Update

1 Mins read
Oil Market Update On Tuesday, crude oil futures prices were lower, while refined product contracts were experiencing a second consecutive day of…

Leave a Reply

Your email address will not be published. Required fields are marked *